Doctors seek best order for Last-Line cancer drugs
NCT ID NCT05839951
Summary
This study looked back at medical records to learn which sequence of two approved drugs helps people with advanced colorectal cancer live longer after other treatments stop working. Researchers analyzed data from 818 patients who received the drugs regorafenib and TAS-102 in different orders as part of their normal care. The goal was to understand real-world outcomes, side effects, and survival to help guide future treatment decisions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Many locations
Whippany, New Jersey, 07981, United States
Conditions
Explore the condition pages connected to this study.